BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10100593)

  • 1. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
    DeMario MD; Ratain MJ; Vogelzang NJ; Mani S; Vokes EE; Fleming GF; Melton K; Johnson S; Benner S; Lebwohl D
    Cancer Chemother Pharmacol; 1999; 43(5):385-8. PubMed ID: 10100593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for phase I study of UFT plus leucovorin and oral JM-216.
    DeMario MD; Ratain MJ
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):26-9. PubMed ID: 9348563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase I study of orally administered UFT plus l-leucovorin].
    Horikoshi N; Aiba K; Kanamaru R; Hasegawa K; Takeda S; Taguchi T; Niitani H; Furue H; Kurihara M; Ogawa M; Abe T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):531-9. PubMed ID: 9530359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
    Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
    Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I
    Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
    Tedesco KL; Berlin J; Blanke CD; Teng M; Choy H; Roberts J; Beauchamp RD; Leach S; Wyman K; Tarpley J; Shyr Y; Caillouette C; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1364-70. PubMed ID: 15817338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
    Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
    Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.
    Hoff PM; Janjan N; Saad ED; Skibber J; Crane C; Lassere Y; Cleary KR; Benner S; Randolph J; Abbruzzese JL; Pazdur R
    J Clin Oncol; 2000 Oct; 18(20):3529-34. PubMed ID: 11032595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.
    González Barón M; Feliu J; Ordoñez A; Colmenarejo A; Espinosa E; Zamora P; de la Gandara I; Jalon JI
    Anticancer Res; 1993; 13(3):759-62. PubMed ID: 8317909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of paclitaxel, UFT, and leucovorin.
    Gojo I; Tkaczuk KH
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):76-8. PubMed ID: 11098500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Park YT; Kim JG; Kim JS
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):119-23. PubMed ID: 9348583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.